Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTXR
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
CTXR
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

CTXR Similar Chart Price Prediction

The price of CTXR is predicted to go up -21%, based on the high correlation periods with TDC. The similarity of these two price pattern on the periods is 96.19%.

stocks logo

CTXR

stocks logo

TDC

Down: -21%Similarity: 96.19%

CTXR Revenue Forecast

CTXR EPS Forecast

CTXR FAQs

What is bull’s view on CTXR?

CTXR stock has a bullish outlook with a price target of $9, as per D. Boral Capital's recent upgrade. This optimism is driven by the anticipated launch of Lymphir, an immunotherapy for cutaneous T-cell lymphoma, which is expected to be a significant value driver. The current price of $3.33 offers substantial upside potential of over 170%.

What is bear's view on CTXR?

CTXR stock is currently trading at $2.74, significantly below its recent price target of $9. Bearish sentiment arises from its recent 14.2% drop following a $3 million direct offering, which diluted shareholder value and raised concerns about financial stability. Additionally, its overbought RSI of 86.04 suggests potential for further downside correction.

What is CTXR revenue forecast for next quarter？

The market consensus for CTXR's revenue in the upcoming quarter is projected to be approximately $2.667M USD.

What is CTXR eps forecast for next quarter？

The market consensus for CTXR's eps in the upcoming quarter is projected to be approximately $1.25 USD.

CTXR VS S&P500

Ask Intellectia about CTXR

CTXR Analyst's Forecast

Jason Kolbert

D. Boral Capital

Hold → Strong Buy

Price Target

$9

Upside

+130.18%

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.
Jason Kolbert

D. Boral Capital

Strong Buy → Hold

Price Target

n/a

Upside

0%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free